Article	Outcome definition	Time point	Azelastine	Placebo	Number of participants randomised (n) and comment
Canonica 2003	Investigator’s assessment of change in clinical sum score (itching, redness) (range 0‐6)	7 days	Investigator: day 7 Mean sum scores (SD) 1.8 (1.4) Participants: Mean score (itching and conjunctiva redness) 1.65 at day 14	Investigator: day 7 Mean sum scores (SD) 3.1 (1.5) Participants: Mean score (itching and c. redness) 3.85 at day 14	n = 139 Main variable: Time course of sum score of main eye symptoms at day 7 Secondary outcomes: symptoms day 21, 42
Giede‐Tuch 1998	Participants’ (responders) rate sum score (itching, lacrimation, redness) decreased by at least 3 score points between day 0‐3; Investigators’ composite symptom mean score (itching, lacrimation, redness)	14 days	Participants’ response rate at day 3 (0.025% and 0.05%): 73% and 82%, respectively Investigator: Mean score of three symptoms (0.05% dose) 7 days 2.4	Participants’ response rate: 56% Investigator: Mean score of 3 symptoms, 7 days 3.5	n = 151 Investigators’ mean estimated from graph (no SD)
James 2003	Investigator’s composite sum symptom score (itching, tearing, conjunctival redness) (range 0‐9), participant’s composite symptom score (itching, redness, tearing) (range 0‐9)	14 days	Investigator: Mean score 2.2 Participant: Mean score 1.9	Investigator: Mean score 2.9 Participant: Mean score 2.8	n = 144 Mean scores estimated from the graphs (no SD). Days 3 and 7 also available (investigator‐reported); days 1‐14 available (participant‐reported)
Lenhard 1997	Investigator’s composite sum symptom score (itching, tearing, conjunctival redness) (range 0‐9) (Secondary analysis)	7 and 14 days	Investigator: Mean score of 3 symptoms (itching, lacrimation, and c. redness) 2.0 at day 14	Investigator: Mean score of 3 symptoms (itching, lacrimation, and c. redness) 2.1 at day 14	n = 278 Mean scores (no SD) due to high variability for itching and marked placebo response, a secondary, more objective analysis was performed Participant‐reported itching, c. redness, lacrimation, and swollen eyelids on a 0‐3 scale
Nazarov 2003	Investigator’s composite sum symptom score (itching, conjunctival redness) on day 7	7 days	Investigator: sum score 1.9 day 14 (estimated from graph)	Investigator: sum score 3.0 day 14 (estimated from graph)	n = 116 Secondary variables: outcomes measured days 21, 42 Participant‐reported symptoms: used to corroborate clinical assessments
Petzold 2002 (ID 3021)	Investigator’s assessment of severity score for both (itching, redness) and separated for each symptom (itching, redness) (range 0‐3)	3 and 14 days	Investigator: Mean score day 14 0.53	Investigator: Mean score day 14 1.39	ID 3021: n = 78 ID 3062: n = 145 ID 3034: n = 240 Treatment duration of 14 days (2 studies) or 28 days (1 study)
Petzold 2002 (ID 3062)			Investigator: Mean score day 14 0.73	Investigator: Mean score day 14 0.76
Petzold 2002 (ID 3034)			Investigator: Mean score day 14 0.76	Investigator: Mean score day 14 1.10
Sabbah 1998	Investigator’s responders rate based on decrease of at least 3 points in the sum symptom score (itching, conjunctival redness, lacrimation) (range 0‐9) between day 0 to 3; participant’s composite sum symptom score (itching, conjunctival redness, lacrimation) (range 0‐9)	3 and 14 days	Investigator: Mean sum scores 1.85 (no SD) at day 14 Investigator: Difference in the mean sum score (itching, conjunctival redness, and lacrimation) ‐5.4 (2.3) at day 14	Investigator: Mean sum scores 2.45 (no SD) at day 14 Investigator: Difference in the mean sum score (itching, conjunctival redness, and lacrimation) ‐3.4 (3.0) at day 14	n = 113 Investigators’ mean estimated from graph (no SD) Participant‐reported data as response rate (n, %) for composite sum symptom score (itching, conjunctival redness, and lacrimation) at days 3 and 14